Date/Time: February 20; 3:00 pm ET
Speaker: LisaAnn Trembath
This webinar is a short course on how to optimize pharmacokinetic and biodistribution sampling for clinical trials of radiopharmaceuticals. Anyone who participates in dosimetry or early phase trials, collects radioactive blood samples, processes or counts samples, or records data from blood sampling will benefit from this overview of basic principles and practical tips. (Urine and fecal sampling are not covered in this talk.) The following concepts will be reviewed: definition of pharmacokinetics and biodistribution; ADME; sampling whole blood, plasma, and serum; proper storage and labeling of samples. In addition, a list of common pitfalls and how to avoid them will be provided in this course.
Date: April 24; 3:00 pm ET
Speaker: Jonathon Nye, PhD
The standardization of computed tomography (CT) in conjunction with PET and SPECT imaging in research trials has been somewhat overlooked. While much is discussed on providing methods for accurate and reproducible PET/SPECT acquisitions, many protocols do not include specific guidelines for the CT that is also being performed. This webinar will discuss technical aspects of computed tomography when used in conjunction with single photon and positron emission tomography (SPECT and PET) including an overview of available CT instrumentation for SPECT and PET, application of CT for attenuation, methods to address spatial mismatch and artifacts and low-dose protocols.
Date: June 26; 3:00 pm ET
Speaker: Adam Opanowski
PET is an imaging technique that uses radiolabeled molecules to successfully image molecular interactions of specific biological processes in vivo. It has been utilized to diagnose, evaluate and manage treatment for a number of different disease processes and, most recently, has seen expanded use in brain imaging. As such, nuclear medicine technologists must have a very clear understanding of the principles and techniques used to image patients with different types of brain abnormalities such as cerebral malignancy, movement disorders and dementia. From patient pre- and post-arrival preparation to the final image analysis, the imaging staff must be aware of the different nuances associated with brain PET imaging including indications, contraindications, radiotracer administration and image acquisition and reconstruction parameters. This session is intended to be an introduction for nuclear medicine technologists and other imaging staff on brain imaging and will provide the attendee with valuable steps to follow to obtain the highest quality of images possible.
Date: August 21; 3:00 pm ET
Speaker: David Schuster, MD
One of the most pressing clinical dilemmas facing physicians who work with patients with prostate cancer is that of the patient with adenocarcinoma of the prostate, post local therapy and now experiencing biochemical failure. Existing imaging techniques, including CT, MRI, and ultrasound, are not optimal for differentiating local from distant recurrence. Local salvage treatments are an option, but successful outcomes may significantly increase if the actual site(s) of recurrence were identified a priori to ensure that distant disease is identified which would change the approach to the patient. anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC), a synthetic amino acid PET radiotracer, has shown promise in staging and restaging patients with prostate cancer. This webinar will present the current status of using FACBC and results of key clinical trials.
Date: October 23; 3:00 pm ET
Speaker: David Dick, PhD
Gallium-68-DOTA compounds that target somatostatin receptors have been used with PET to significantly improved the quality of imaging neuroendocrine tumors. Although approved in Europe, this class of agent has only been used in investigational trials under INDs in the US. Expanded efforts are underway to move them towards approval and into clinical practice. Recently, both 68Ga-DOTATOC and 68Ga-DOTATATE (GalioMedix ™) were granted orphan drug status by the FDA for the management of neuroendocrine tumors. These announcements have garnered widespread interest and elevated enthusiasm for using gallium imaging agents, but some issues related to using these agents remain unclear. This webinar will describe the current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC) along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use.
Date: December 11; 3:00 pm ET
Speaker: Maria Carrillo, PhD
Although the Centers for Medicare & Medicaid Services (CMS) denied coverage to Medicare beneficiaries for any clinical use of the technology, they left the door open for future approval pending more data on the benefits of amyloid imaging. In a process known as “coverage with evidence development” (CED), the agency will pay for a single scan for people participating in clinical trials designed to gather evidence about health outcomes. It would accept short-term outcomes such as a change in medication or avoidance of unnecessary tests as sufficient evidence of a health benefit. This webinar will present the status of the community’s efforts during the year following CMS’s initial decision to collect additional data and provide an update by CMS on CED,